Literature DB >> 12238944

Information barriers to the implementation of economic evaluations in Japan.

Shuzo Nishimura1, George W Torrance, Naoki Ikegami, Shunichi Fukuhara, Michael Drummond, François Schubert.   

Abstract

With increasing cost-containment pressures within healthcare systems worldwide, economic evaluations of medical technologies, particularly pharmaceuticals, are used to aid the allocation of expenditure and resources. Facing similar pressures, Japan will probably also introduce economic evaluation of health technology. However, the structure of the healthcare system in Japan does not lend itself naturally to the collection of the epidemiological and cost data required for economic evaluations in medicine. In addition, there are no formal methodological guidelines in place for these analyses. To overcome these information barriers in Japan, progress may be aided by the adoption of approaches used in other countries for data collection and guideline development.

Mesh:

Year:  2002        PMID: 12238944     DOI: 10.2165/00019053-200220002-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Authors:  Naoki Ikegami; Michael Drummond; Shunichi Fukuhara; Shuzo Nishimura; George W Torrance; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  A comparative review of pharmacoeconomic guidelines.

Authors:  P Jacobs; J Bachynsky; J F Baladi
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

4.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

5.  Canada's new guidelines for the economic evaluation of pharmaceuticals.

Authors:  D Menon; F Schubert; G W Torrance
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

6.  Economic evaluation of neonatal intensive care of very-low-birth-weight infants.

Authors:  M H Boyle; G W Torrance; J C Sinclair; S P Horwood
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

  6 in total
  3 in total

Review 1.  Practical aspects of designing and conducting pharmacoeconomic studies in Japan.

Authors:  Jim Doherty; Keiko Sato
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  The development and use of quality-of-life measures to evaluate health outcomes in Japan.

Authors:  Shunichi Fukuhara; Naoki Ikegami; George W Torrance; Shuzo Nishimura; Michael Drummond; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Authors:  Naoki Ikegami; Michael Drummond; Shunichi Fukuhara; Shuzo Nishimura; George W Torrance; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.